Quadramet may have direct anticancer activity

Published: 1-Aug-2004

A study relating to Cytogen's Quadramet (samarium Sm-153 lexidronam injection), presented at the ASCO meeting, has suggested that it may have direct anticancer activity.


A study relating to Cytogen's Quadramet (samarium Sm-153 lexidronam injection), presented at the ASCO meeting, has suggested that it may have direct anticancer activity.

A single centre phase I/II study evaluated the toxicity and efficacy of systemic therapy given in combination with Quadramet, a targeted oncology agent, in patients with hormone refractory prostate cancer. Patients were first treated with fixed doses of both paclitaxel and estramustine, and were then treated with Quadramet, in a dose escalation fashion. Phase I data has demonstrated an overall response rate of 75%.

Quadramet is currently available as a non-narcotic alternative for rapid and long-acting pain relief from bone metastases associated with prostate, breast, multiple myeloma and other cancers.

You may also like